Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 428.55 INR
Change Today 0.00 / 0.00%
Volume 0.0
As of 6:06 AM 11/17/15 All times are local (Market data is delayed by at least 15 minutes).

shasun pharmaceuticals ltd (SAPH) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/17/15 - 433.00
52 Week Low
12/17/14 - 244.50
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

shasun pharmaceuticals ltd (SAPH) Related Businessweek News

No Related Businessweek News Found

shasun pharmaceuticals ltd (SAPH) Details

Shasun Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and formulations to the pharmaceutical industry primarily in India. The company offers API products in the areas of pain management and musculoskeletal, central nervous system, cardiovascular, hyperphosphataemia, COPD, anti-infective, gastrointestinal, gastrointestinal, cough suppressants, and anti-emetic. It also engages in the contract research and manufacturing services business, which provides chemistry and analytical services; and offers formulation development and manufacturing services for solid dosage products to pharmaceutical customers. In addition, it offers enteric coating excipients and generic products. The company also exports its products to North America, Europe, rest of Asia, and Latin America. The company was formerly known as Shasun Chemicals and Drugs Ltd. Shasun Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Chennai, India. As of November 19, 2015, Shasun Pharmaceuticals Ltd operates as a subsidiary of Strides Shasun Limited.

Founded in 1976

shasun pharmaceuticals ltd (SAPH) Top Compensated Officers

Chief Executive Officer, Managing Director, W...
Total Annual Compensation: 13.0M
Chief Financial Officer
Total Annual Compensation: 8.6M
Director of Operations & EHS and Whole Time D...
Total Annual Compensation: 3.6M
Wholetime Director
Total Annual Compensation: 8.6M
Whole-Time Director and Member of Corporate S...
Total Annual Compensation: 8.6M
Compensation as of Fiscal Year 2015.

shasun pharmaceuticals ltd (SAPH) Key Developments

Shasun Pharmaceuticals Forced to Close Tamil Nadu Pharmaceutical Factory Following Fire

Shasun Pharmaceuticals has announced that government authorities have requested the company to suspend production at its active pharmaceutical ingredient (API) manufacturing facility in Cuddalore, Tamil Nadu. The measure follows the outbreak of a fire at a new block at the factory during testing. Shasun reported that one factory worker was killed in the fire, while another suffered injuries and was hospitalized.

Strides And Shasun Seeks To Raise Money

Strides Arcolab Ltd. (BSE:532531) post acquisition of Shasun Pharmaceuticals Ltd (BSE:524552) is planning to raise INR 15 billion to fund expansion, debt repayment and other corporate purposes and has sought fresh approval from its shareholders. "In order to fund capital expenditure, long-term working capital, investments, expansion of the existing business, debt repayment and other approved corporate purposes, the company proposes to raise up to Rs 1,500 crore in one or more trenches," Strides Shasun said a filing to BSE.

Shasun Pharmaceuticals Limited Receives USFDA Approval for Carisoprodol Tablets

Shasun Pharmaceuticals Limited announced that it has received approval from the United States Food & Drug Administration (USFDA) for Carisoprodol Tablets USP 250 mg and 350 mg. Carisoprodol Tablets 250 mg & 350 mg has sales of approximately USD 38 million. While the 350 mg has few Generic players, Shasun expects to be the first marketed generic player in the USD 16 Million Carisoprodol Tablets 250 mg opportunity. The product will be manufactured at the Pondicherry facility of the company and distributed in US through a partner. The product is expected to be launched shortly.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SAPH:IN 428.55 INR 0.00

SAPH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 817.00 INR -7.10
Dishman Pharmaceuticals & Chemicals Ltd 310.40 INR -9.85
Divi's Laboratories Ltd 1,146 INR +16.65
Jubilant Life Sciences Ltd 408.90 INR -4.95
Piramal Enterprises Ltd 966.30 INR -14.60
View Industry Companies

Industry Analysis


Industry Average

Valuation SAPH Industry Range
Price/Earnings 60.1x
Price/Sales 2.1x
Price/Book 6.3x
Price/Cash Flow 28.5x
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SHASUN PHARMACEUTICALS LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at